Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Anxiolytic Candidate in Generalized Anxiety Disorder
A new-protocol amendment and an annual report are different submissions with different purposes, clocks, and content, and treating one as a substitute for the other is a common source of regulatory error. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral anxiolytic candidate in a blinded, placebo-controlled Phase 2 dose-ranging study (96 of 240 planned adults entered). It reconciles enrollment, tabulates participants by age, sex, and race, reports blinded pooled safety data, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, drafts Form FDA 1571 entries and a cover letter, and builds a timeline to a December 31, 2027 deadline. It also explains why Canadian clinical trial filings run on separate tracks, and why an unknown count must never be reported as zero.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Dorcas Koomson
- Peivand Pirouzi
- Gloria Anthonia Amoateng Agyemang
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24419701
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00